Paediatric lung transplant outcomes vary with Mycobacterium abscessus complex species

European Respiratory Journal

Volumn 41, Issue 5, 2013, Pages 1230-1232

  Robinson, Paul D ^a,b   Harris, Kathryn A ^b   Aurora, Paul ^b   Hartley, John C ^b   Tsang, Victor ^b   Spencer, Helen ^b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; COTRIMOXAZOLE; ETHAMBUTOL; IMIPENEM; ISONIAZID; LINEZOLID; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE;

ADOLESCENT; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; INFECTION RISK; LETTER; LUNG TRANSPLANTATION; MYCOBACTERIUM ABSCESSUS; NONHUMAN; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; CHILD; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; TREATMENT OUTCOME;

EID: 84877093887     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00143512     Document Type: Letter

References (10)

1. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
2. Huang HC, Weigt SS, Derhovanessian A, et al. Non-tuberculous Mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011; 30: 790-798.
3. Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61: 507-513. (Pubitemid 43901521)
4. De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010; 29: 1395-1404.
5. Adekambi T, Berger P, Raoult D, et al. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56: 133-143. (Pubitemid 43125908)
6. Blauwendraat C, Dixon GL, Hartley JC, et al. The use of a twogene sequencing approach to accurately distinguish between the species within the Mycobacterium abscessus complex and Mycobacterium chelonae. Eur J Clin Microbiol Infect Dis 2012; 31: 1847-1853.
7. Catherinot E, Clarissou J, Etienne G, et al. Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect Immun 2007; 75: 1055-1058. (Pubitemid 46203473)
8. Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25: 1447-1455. (Pubitemid 44909461)
9. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183: 405-410.
10. Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-781.